Biogen Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 6/6
Biogen has a total shareholder equity of $16.4B and total debt of $6.3B, which brings its debt-to-equity ratio to 38.5%. Its total assets and total liabilities are $28.3B and $12.0B respectively. Biogen's EBIT is $2.3B making its interest coverage ratio 11.9. It has cash and short-term investments of $1.7B.
Anahtar bilgiler
38.5%
Borç/özkaynak oranı
US$6.29b
Borç
| Faiz karşılama oranı | 11.9x |
| Nakit | US$1.70b |
| Eşitlik | US$16.36b |
| Toplam yükümlülükler | US$11.95b |
| Toplam varlıklar | US$28.31b |
Son finansal sağlık güncellemeleri
Does Biogen (NASDAQ:BIIB) Have A Healthy Balance Sheet?
Oct 01
Is Biogen (NASDAQ:BIIB) Using Too Much Debt?
May 23Here's Why Biogen (NASDAQ:BIIB) Can Manage Its Debt Responsibly
Jan 31Is Biogen (NASDAQ:BIIB) Using Too Much Debt?
Oct 03Biogen (NASDAQ:BIIB) Has A Pretty Healthy Balance Sheet
Jun 28Recent updates
Biogen Q3 Earnings Review: Why I Remain Optimistic Despite Difficult Quarter
Oct 31Does Biogen (NASDAQ:BIIB) Have A Healthy Balance Sheet?
Oct 01What You Can Learn From Biogen Inc.'s (NASDAQ:BIIB) P/E
Sep 04Biogen: Q2 Earnings, Share Price May Have Bottomed Out As CEO Makes Mark
Aug 17Biogen Stock: Cheapish, But With Few Growth Prospects
Jul 11Is Biogen (NASDAQ:BIIB) Using Too Much Debt?
May 23Biogen's Revenue Dip Meets Cost Cuts In Q1 (Rating Upgrade)
Apr 29Earnings Update: Biogen Inc. (NASDAQ:BIIB) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts
Apr 28The Price Is Right For Biogen Inc. (NASDAQ:BIIB)
Apr 15We Think You Can Look Beyond Biogen's (NASDAQ:BIIB) Lackluster Earnings
Feb 21Biogen Inc. Just Missed EPS By 21%: Here's What Analysts Think Will Happen Next
Feb 16Biogen's Q4 Earnings Disappoint Amidst Strategic Challenges (Rating Downgrade)
Feb 14Here's Why Biogen (NASDAQ:BIIB) Can Manage Its Debt Responsibly
Jan 31Biotech And Pharma Diversification Pays Off
Jan 25Getting In Cheap On Biogen Inc. (NASDAQ:BIIB) Might Be Difficult
Dec 26An Intrinsic Calculation For Biogen Inc. (NASDAQ:BIIB) Suggests It's 49% Undervalued
Oct 21Is Biogen (NASDAQ:BIIB) Using Too Much Debt?
Oct 03Is Biogen Inc. (NASDAQ:BIIB) Trading At A 31% Discount?
Jul 16Biogen (NASDAQ:BIIB) Has A Pretty Healthy Balance Sheet
Jun 28Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: BIIB's short term assets ($6.8B) exceed its short term liabilities ($5.4B).
Uzun Vadeli Yükümlülükler: BIIB's short term assets ($6.8B) exceed its long term liabilities ($6.5B).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: BIIB's net debt to equity ratio (28.1%) is considered satisfactory.
Borcun Azaltılması: BIIB's debt to equity ratio has reduced from 42.5% to 38.5% over the past 5 years.
Borç Kapsamı: BIIB's debt is well covered by operating cash flow (33.8%).
Faiz Kapsamı: BIIB's interest payments on its debt are well covered by EBIT (11.9x coverage).